As global regulators and scientific communities continue to push for more predictive, human-relevant, and ethical approaches to safety testing, in vitro toxicology has emerged as a critical component of modern drug development. Once seen primarily as an early...
Turning AI Skeptics into AI Advocates Through High-Integrity Data
For years, biopharma has accumulated vast volumes of data. Now, as the industry races toward an AI-driven future, that data must become a true strategic asset. Recent research shows that while 95% of biopharma companies are actively pursuing AI initiatives in...
Oral vs Injectable GLP-1s: The 2026 Weight Loss Drug Shift
The arrival of two approved oral GLP-1 weight loss therapies in the space of four months has fundamentally redrawn the obesity treatment landscape in 2026. For years, the question of whether a daily pill could ever match the efficacy of a weekly injection was largely...
Radiopharmaceuticals: The Cancer Treatment Reshaping Oncology
For decades, oncology ran on a handful of dominant modalities: surgery, chemotherapy, and radiotherapy, later joined by targeted therapies and immunotherapy. Radiopharmaceuticals have now entered that conversation as a serious contender. These drugs combine a...
China Drug Trials Now Outpace the US. Here is What That Means
China has overtaken the United States in the annual number of drug clinical trials. It is a sentence that would have seemed implausible a decade ago. Today, it is simply fact, and the implications for drug development, global pharma strategy, and geopolitical...
Why Biopharma Must Invest in Novel Targets
Drug development continues to concentrate on a small set of well-known targets, creating a crowded landscape where many companies pursue similar pathways. While research into novel mechanisms continues, familiar targets often take priority, reflecting a cautious...
Yaqrit Phase 2a Data, Clinical Consensus Boost YAQ007 and YAQ006 in HE
• Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE) • Phase 2a results of YAQ007 (oral OPA) show ammonia reduction • Utility of rifaximin in HE defined more narrowly LONDON, April 17, 2026 (GLOBE NEWSWIRE) -- Yaqrit, a...
The Rising Reach of Black-Market Prescription Drugs in the UK
Despite common perceptions, the black market is no longer confined to underground, organised crime networks or obscure corners of the internet. In reality, this trade in illegal prescription drugs can be found in a local corner shop, hair salon, or even people’s own...
From Flower to Pharmacy: The Science Behind Manuka Honey
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Breakthroughs in the Lab – Blind Spots in Reality
Obesity care is at a turning point. GLP-1s like Ozempic and Mounjaro have upended weight loss culture – and the research backs them up. For the first time, multiple randomized trials have found that anti-obesity medications can lead to an average 15-20% weight loss....
Why Pharma’s Commercial Model is Failing Precision Medicine
Pharma generates more insight than ever. Translating that insight into timely action is where the system falters, and the gap runs deeper than most commercial leaders are willing to admit. Over the past decade, omnichannel systems have matured considerably. CRM...
Life Science and Biopharma in 2026: Insights from L.E.K. Consulting
The biopharma industry is at an inflection point as it enters 2026. Discoveries from the past year will be applied and scaled, particularly across AI-enabled drug development, advanced modalities and cardiometabolic disease treatment. These advancements will occur...
Understanding GLP-1 Side Effects Through a Nutritional Lens
GLP-1 medications have changed the landscape of weight management. For many people, they have delivered clinically meaningful weight loss alongside improvements in glycaemic control, and their place in treatment pathways is now well established. What is becoming...
European Life Sciences: Rethinking the “Organic” US Expansion
Against a backdrop of rising development and launch costs, growing regulatory complexity, geopolitical uncertainty and intensifying competition for specialist talent, many European pharma and biotech companies are reassessing the long-held ambition of “cracking the...
J&J to Invest Over $1B in Pennsylvania Cell Therapy Manufacturing Facility
Johnson & Johnson has announced plans to invest more than $1 billion in a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. This project marks a significant expansion of its advanced therapies infrastructure and reinforces the company’s...
Raising Expectations for Medical Liaisons
In the last decade, the Medical Science Liaison role has evolved from a scientific messenger to a field based strategist operating in one of the most highly scrutinized environments in healthcare. That evolution is why board certification is moving from optional...
Thousands Benefit From New Treatment for Advanced Prostate Cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment. Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23...
Novo Nordisk and Aspect Biosystems Expand Diabetes Collaboration
Novo Nordisk and Aspect Biosystems expand collaboration to accelerate curative diabetes therapies The landscape of regenerative medicine has shifted significantly following the announcement that Novo Nordisk and Aspect Biosystems are entering a comprehensive new phase...







